摘要
三阴性乳腺癌为雌、孕激素受体及人表皮生长因子受体-2均为阴性的乳腺癌,由于缺乏特异性的治疗靶点,晚期治疗尚缺少有效的治疗方案。本文综述近年来晚期三阴性乳腺癌的药物治疗研究进展,主要包括化学治疗、靶向治疗、内分泌治疗、免疫治疗四个方面,旨在为临床治疗提供借鉴和参考。
Triple-negative breast cancer is estrogen receptor,progesterone receptor and human epidermal growth factor receptor-2 negative breast cancer.The lack of specific treatment targets,there are few effective therapy for advanced triple-negative breast cancer.This article will review the current progress in drug therapy for advanced triple-negative breast cancer,including chemotherapy,targeted therapy,endocrine therapy and immunotherapy,in order to provide reference for clinical treatment.
作者
赵全铭
杨洋
ZHAO Quanming;YANG Yang(Second Clinical Medical College of Shanxi Medical University,Taiyuan 030001,Shanxi,China;College of Pharmacy,Chongqing Medical University,Chongqing 400016,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2020年第4期475-480,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
重庆市技术创新与应用发展专项面上项目(cstc2019jscx-msxmX0096)。
关键词
三阴性乳腺癌
化学治疗
靶向治疗
内分泌治疗
免疫治疗
triple-negative breast cancer
chemotherapy
targeted therapy
endocrine therapy
immunotherapy
